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Study of Epigenetic Changes Leads to
Treatment Advances in Adult Leukemias
by Katie Prout Matias

s researchers in the exciting new field
of study called epigenetics have found,
genetic alterations are not the only
genomic abnormality to play a major
role in the development of cancer. Modifications
in gene expression may be just as important as
changes in gene structure when it comes to
promoting cancer formation.

Dr. Guillermo GarciaManero , an assistant

professor in the Depart,
ment of Leukemia, is
building a database of
epigenetic changes in acute
lymphoblastic leukemia
(ALL) that could be used
to analyze different kinds
of ALL and develop risk,
adaptive therapies .

Most of these epigenetic changes arise
spontaneously as a function of age and
predispose cells to cancer transformation,
according to Jean,Pierre Issa, M.D., an
associate professor in the Department
of Leukemia at The University of
Texas M. D. Anderson Cancer Center.
Environmental factors such as exposure
to carcinogens, viral infections, and
diet may also play a role.
"Leukemias have more epigenetic
changes than other malignancies,
followed closely by colon cancer,"
said Dr. Issa. "It could be that epige,
netic information is particularly
important in leukemias."

Understanding the mechanisms
of epigenetic change
By identifying and targeting
the two main mechanisms of
abnormal gene expression( Continued on next page)
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Study of Epigenetic Changes in Adult Leukemias
(Continued from page 1)
DNA methylation and histone modifica,
tion-researchers are finding new ways
to treat adult patients with leukemia.
DNA methylation, the addition
of a methyl group to one of the bases
of DNA, is a fundamental part of gene
expression. The abnormal addition,
removal, or placement of these groups,
however, can lead to the loss of gene
expression and to the activation or
inactivation of important genes, such
as tumor suppressor genes, DNA repair
genes, and angiogenesis genes, said Dr.
Issa. Abnormal DNA methylation
occurs in most cancers.
The removal of acetyl groups, or
histone deacetylation, allows the
histones to bind to the DNA and keep
it tightly wrapped so that cellular
switches cannot access the genes to
turn them on or off. "It is now thought
that DNA methylation leads to histone
changes and vice versa, so there is a
loop that makes sure that the genes
that are turned off by these mechanisms
remain turned off," said Dr. Issa. With,
out intervention, these changes in gene

and protein expression are passed on
to future generations of cells.

Restoring normal
gene expression
Unlike genetic changes, however,
epigenetic changes can be reversed.
Researchers are investigating drugs
that can inhibit histone deacetylation
and strip DNA of the methyl group
tags, thus restoring gene expression.
Investigators at M. D. Anderson
are studying a new inhibitor of histone
deacetylation called suberoylanilide
hydroxamic acid (SAHA). When
SAHA reverses histone deacetylation,
the DNA unwraps from the histone
core, allowing the genes to be activated.
In the study, researchers are measuring
histone changes before and after treat,
ment in patients with acute myelog,
enous leukemia (AML).
In the area of DNA methylation,
researchers are taking a second look at
an older drug. Decitabine, which was
developed in Czechoslovakia in the
1960s, is an analogue of cytosine that
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inhibits the methylation of certain
genes. Hypomethylating drugs such as
decitabine show promise for the treat,
ment of leukemia, particularly when
used in combination with other agents.
In an upcoming clinical trial, research,
ers at M. D. Anderson will study the
effects of decitabine combined with
imatinib (Gleevec) in previously
untreated patients with advanced
(accelerated or blast phase) chronic
myelogenous leukemia (CML) and in
patients with refractory or imatinib,
resistant CML.

Improving the outlook
for patients with CML
Although it does not affect genetic
expression, imatinib-a new and, so
far, highly successful drug-is a targeted
treatment that specifically blocks the
protein of the fusion BCR,ABL gene
that causes and marks CML.
"The perfect drug for cancer is sort
of like imatinib: a drug that would target
and kill only the cancer cells and not
give you any side effects," said Jorge E.
Cortes, M.D. , an associate professor in
the Department of Leukemia. "It has
changed the treatment of CML."
lmatinib often helps patients in whom
interferon and other treatments have
failed and produces a complete cytogenetic
response in more than 60% of previously
untreated patients, while causing very few
adverse effects. However, no long,term
data exist regarding the durability of this
response. In some patients, especially those
with advanced stages of CML, the cancer
does not respond to imatinib, and in
others, the disease stops responding and
becomes resistant.
"lmatinib is very new, and the
failures to imatinib are only now
starting to appear," said Dr. Cortes.
"We need to look at other treatments
for patients in whom imatinib fails.
Those patients with advanced disease
are the perfect candidates to start from
the beginning with a combination
treatment based on imatinib."

Chromatin Compacted, Silenced

Researchers at M. D. Anderson are investigating the use of such drugs as decitabine
and suberoylanilide hydroxamic acid ( SAHA) to reverse the two main mechanisms of
epigenetic changes, DNA methylation and histone deacetylation .
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Using epigenetic patterns to
predict treatments, outcomes
While combination therapy using
imatinib and decitabine could improve

"It could be that
epigenetic
information is
particularly
important in
leukemias."
- Jean-Pierre Issa, M.D.,
associate professor,
Department of Leukemia
Photo by F. Carter Smith

the treatment response rates for patients
with CML even more, progress in the
treatment of other leukemias has not
been as great. "In many other leukemias,
especially AML, the signaling pathways
that tum these cells leukemic are
probably much more complex," said
Stefan Faded, M.D., an assistant
professor in the Department of Leukemia.
"Imatinib is a rather specific tyrosine
kinase inhibitor that works very well in
BCR-ABL-positive CML, but AML has
proved much more resistant to this type
of approach. Inhibiting a single signaling pathway will most likely not be
sufficient in AML."
For these other leukemias-including
AML, chronic lymphocytic leukemia
(CLL), acute lymphoblastic leukemia
(ALL), and myelodysplastic syndrome
(MDS)-epigenetics may offer hope,
not in drug development but through
disease profiling and classification.
Because different leukemias have
distinct epigenetic patterns that are
correlated with outcome and response
to therapy, physicians are already
using certain combinations of
methylated genes to determine
prognosis and treatment for subsets
of patients.
Guillermo Garcia-Manero, M.D.,
an assistant professor in the Department
of Leukemia, is building a database of
epigenetic changes in ALL. "What is
fascinating about A LL is that it is a
very heterogeneous group of disorders.
Although we call it one name, it is
probably multiple diseases. And they
have varying prognoses," said Dr.
Garcia-Manero.
A certain combination of genes in
ALL, when epigenetically inactivated,

seems to result in a very unfavorable
outcome for patients. This is important
because if these patients do not have
the Philadelphia ch romosome, wh ich
is associated with a very poor prognosis,
they are treated as if they have the
more curable form of ALL. In fact,
they should rece ive the same aggressive

treatment, such as early bone marrow
transplantation, given to Philadelphia
chromosome-positive patients. Dr.
Garcia-Manero suggested that patients
with this epigenetic abn ormality also
might benefit from h ypometh ylating
agents or histone modifiers in combination with chemotherapy.
"If we are successful and can correlate and confirm some of these results,
then this will evolve into developing
risk-adaptive therapies to determine
who's going to do what and treat them
with therapy based on their molecular
and epigenetic profiles," said Dr.
Garcia-Manero. •
FOR MORE INFORMATION , contact Dr. Issa at
(713) 745-2260, Dr. Cortes at (713) 7945783, Dr. Faderl at (713) 745-4613, or
Dr. Garcia-Manero at (713) 745-3428 .

PROTOCOLS
Studies Examine Treatment of Leukemia
Clinical trials in progress at The
University of Texas M. D. Anderson
Cancer Center include the following
for patients with chronic myelogenous
leukemia.
•

•

Phase I study of tipifarnib (Zarnestra,
R115777.USA30) and imatinib
mesylate (Gleevec, STl571) in
chronic-phase chronic myelogenous
leukemia (CML) (ID02-169).
Physician: Jorge Cortes, MD.
To be eligible for this study, patients
must be 16 years old or older with
Philadelphia chromosome- or BCRABL-positive CML that failed to
respond to previous therapy with
imatinib mesylate. A Zubrod performance status :s; 2 is required, as are
adequate hepatic and renal function
and a white blood cell count :s; 30 x
109/L. Women who are pregnant or
nursing are not eligible.
Therapy of early chronic-phase
chronic myelogenous leukemia (CML)
with higher-dose imatinib mesylate
(Gleevec, STl571 ), interferon-alpha
(IFN-a), and low-dose cytarabine
(Ara-C) (ID01-151) . Physician.·Jorge
Cortes, M 0.

Participants must be 15 years old or
older with Philadelphia chromosomeor BCR-ABL-positive early chronicphase CML. Patients must have
received no or minimal prior therapy,
except for hydroxyurea. Both male and
female participants must use effective
birth control methods during treatment
and for at least three months afterward.
•

Phase II study of high-dose imatinib
mesylate (Gleevec, STl571) for the
treatment of late chronic-phase chronic
myelogenous leukemia (CML) (ID01292). Physician: Jorge Cortes, MD.
This study is for patients in whom
treatment with interferon-alpha has failed,
patients with late chronic-phase disease
who have not received interferon-alpha,
or patients who refuse to take interferonalpha. Participants must be 15 years old
or older with Philadelphia chromosomeor BCR-ABL-positive early chronicphase CML.

•

A phase 1/11 study of clofarabine
(Clofarex) in combination with
cytarabine (Ara-C) in adult patients
with primary refractory acute myelogenous leukemia (AML) or acute

(Continued on page 4)
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chronic-phase CML that is resistant
or refractory to imatinib mesylate
or be imatinib mesylate intolerant.

Leukemia Studies
(Continued from page 3)
lymphoblastic leukemia (ALL), highrisk myelodysplastic syndrome (MOS),
or blast-phase chronic myelogenous
leukemia (CML) (1002-074). Physician:
Stefan Fader/, M.D.
Participants must be at least 18
years old and have adequate organ
function. Participants of child-bearing
potential must use effective birth control
methods during treatment and for at
least three months afterwards. Exclusion criteria include previous treatment
with clofarabine; active, uncontrolled
systemic disease; symptomatic central
nervous system involvement; and
concurrent chemotherapy.
•

Phase 11 study of imatinib mesylate
(Gleevec, STl571) and decitabine in
chronic myelogenous leukemia (CML)
in accelerated and blast phases (1002205). Physician: Jean-Pierre Issa, M.D.
Patients with a histologically confirmed diagnosis of CML in the accelerated or blastic phase are eligible.
Participants must have discontinued
chemotherapy at least two weeks
prior to entering this study, unless
there is evidence of rapidly progressive
disease. Adequate renal and hepatic
functions and normal cardiac function
are required.

•

A phase II, multicenter study of
decitabine in accelerated-phase
chronic myelogenous leukemia (CML)
that is refractory to imatinib mesylate
(Gleevec, STl571) (OM02-133).
Physician: Jean-Pierre Issa, M.D.
To be eligible, patients must have
Philadelphia chromosome-positive
accelerated-phase CML that is resistant
or refractory to imatinib mesylate or be
imatinib mesylate intolerant. Patients
two years old and older may participate , as long as they have recovered
from any side effects of previous
chemotherapy (with the exception
of hydroxyurea).

•

A phase 11, multicenter study of
decitabine in chronic-phase chronic
myelogenous leukemia (CML) that
is refractory to imatinib mesylate
(Gleevec, STl571) (DM02-134).
Physician: Jean-Pierre Issa, M.D.
To be eligible, patients must be
at least two years old and have
Philadelphia chromosome-positive

I
I

•

A phase 11 , multicenter study of
decitabine in blast-phase chronic
myelogenous leukemia (CML) that
is refractory to imatinib mesylate
(Gleevec, STl571) (DM02-135).
Physician: Jean-Pierre Issa, M.D.
To be eligible, patients must have
Philadelphia chromosome-positive
blast-phase CML that is resistant or
refractory to imatinib mesylate or
be imatinib mesylate intolerant.

•

Phase 11 study of lonafarnib
(SCH66336) and imatinib mesylate
(Gleevec, STl571) in chronic myelogenous leukemia (CML) (1002-221 ).
Physician: Jorge Cortes, M.D.
To be eligible for this study, patients
must be older than 16 years old and
have chronic-phase CML that has failed
treatment with imatinib mesylate alone
or have accelerated- or blast-phase
CML with or without prior treatment
with imatinib mesylate. The patient
must have a Zubrod performance
status of 2 or better with adequate liver
and hepatic function.

•

Randomized trial of early chronicphase chronic myelogenous leukemia
(CML) with high-dose imatinib mesylate
(Gleevec, STl571) alone or in combination with pegylated interferon-alpha-2b
(Peg-lntron) and granulocyte-macrophage colony-stimulating factor (GMCSF, sargramostim, Leukine) (1002534) . Physician: Jorge Cortes, M.D.
To be eligible, patients must have
Philadelphia chromosome-positive
CML in early chronic phase and have
received no or minimal prior therapy
(< 1 month of prior interferon-alpha,
with or without cytarabine [Ara-C] and/
or imatinib mesylate). They must have
a performance status of 0-2 and
adequate liver and renal function.
Women who are pregnant or nursing
are not eligible. •

about these cUnical
trials , physicians or patients may call the
M . D . Anderson Information Line. Those
within the United States should call (800)
392, 1611 ; those in Houston or outside the
United States should call (713) 792,6161.
Visit the M . D. Anderson clinical trials Web
site at www. clinicaltrials .org for a broader
listing of treatment research protocols.
FoR MORE INFORMATION
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by Karen Stuyck

atients who place their
hopes and lives in the
hands of their physi-cians tend to for get
that doctors, despite their
abundant skills and talents,
are only human. In fact , those
who dedicate their lives to caring
for the sick often do so at great
personal cost. And nowhere
is that price higher than in the
fie ld of oncology.

P

The psych ological needs and burdens
of patients with cancer and their
families place a particularly heavy load
on oncologists, according to Walter F.
Baile, M.D., professor and chief of the
Section of Psychiatry in the Department
of Neuro,On cology at The University of
Texas M. D. A nderson Cancer Center.
A 1991 study in the Journal of Clinical
Oncology reported that 56% of medical
oncologists, radiation oncologists, and
surgeons who responded to a survey
were experiencing burnout. The major
reasons cited, according to Dr. Baile,
were "the difficulty of dealing with
patients who d idn't get better and
feeling frustrated that there weren't
more treatmen ts to effect a positive
outcome for these patients."
Many can cer specialists find end,
of, life care grueling, frustrating, and
stressful. "It confronts them with issues
of dying to wh ich little attention h as
been given in th eir training," Dr. Baile
said. "The average oncologist probably
gives bad news 20,000 times during the
course of a career, and there is very little
preparation on h ow to do that well."
A study of British oncologists showed
that 28% had psychiatric disorders, such
as anxiety and depression, due to patient
overload, concern about treatment
toxicity, and low satisfaction with their
work. Another study, this one of Cana,
dian oncologists, found that 53% felt
emotionally exh austed and rated their

♦

I Being an Oncologist

level of personal accomplishment as low.
Many were considering leaving the field
of oncology.
Most physicians possess characteris,
tics that help them provide excellent
patient care but make them more likely
to suffer from burnout, Dr. Baile said.
These traits include working very long
hours, denying their own needs, finding
it difficult to ask for help, sacrificing their
family and personal life for their jobs,
taking a tremendous amount of responsi,
bility for their patients, being very selr
critical, and being unable to say "no" to
requests for additional time and effort.
On the other hand, an important
finding from the study of British
oncologists was that doctors who had
better interpersonal communication
skills were less likely to experience
burnout, probably because they did not
adopt unhelpful "survival tactics," such

as distancing themselves
from their patients, which
can deprive physicians of
an important source of
personal and professional
satisfaction, Dr. Baile said.
Educational programs
are available to help
oncologists communicate
better with their patients.
Dr. Baile participates in a
National Cancer Institutefunded project that con,
ducts a four,day retreat
for medical oncology
fellows twice a year to
address communication
with patients at the end of
life. He is also participating
in an effort by the Ameri,
can Society of Clinical
Oncology to introduce
communication skills
workshops at their
annual meeting.
Patients say that _
physicians who are
compassionate, informa,
tive, respectful, and
pleasant give them hope
for the future. "Physicians
who value caring as much
as curing can have a significant impact
on their patients' morale and optimism,"
Dr. Baile said. "Unfortunately, medical
training often overemphasizes technical
skills at the expense of interpersonal
ones." Physicians with good communi,
cation and interpersonal skills receive
more positive feedback from patients,
which can be a buffer against burnout.
Acknowledging the emotional toll
that their work exacts also can help
oncologists deal with their stress, said
Dr. Baile. But physicians sometimes
have problems discussing the difficulties
of their work. Part of this reluctance is
due to "a principle in the culture of
medicine not to talk about your feelings
regarding patient care, overload, or
burnout," Dr. Baile said. But reluctance
to talk about problems can lead to
irritability, burnout, and a cynical
attitude toward medicine. If the

problems persist, some physicians may
tum to substance abuse or suffer sleep
deprivation and exhaustion.
To help clinicians, as well as re,
searchers, recognize and deal with
workplace stress, M. D. Anderson
formed a Faculty Health Committee,
which is chaired by Ellen R. Gritz,
Ph.D., professor and chair of the
Department of Behavioral Science.
Kathleen Sazama, M.D., J.D., then
vice president for Faculty Academic
Affairs at M. D. Anderson, provided
administrative leadership. The
committee's goal is to help faculty
members recognize the signs of danger,
ous stress and be aware of the mental
health resources available to them.
"We want faculty to be aware of
what amount and type of stress is
normal in the workplace and how to
realize when stress has gone beyond
their ability to manage it. And we
want to let them know what solutions
are available," said Dr. Sazama, now
a professor in the Department of
Laboratory Medicine.
To kick off the Faculty Health
Committee's efforts, John,Henry
Pfifferling, Ph.D., and Louise Andrew,
M.D., J.D., from the Center for Profes,
sional Well,Being in Durham, North
Carolina, will present "Faculty Quality
of Life: An Endangered Topic" on
May 20.
Other resources for dealing with
stress include counseling through
M. D. Anderson's Employee Assistance
Program and a proposed Faculty Assis,
tance Program, a confidential service
that will be staffed by outside mental
health professionals.
Dr. Baile and Janis Apted, director of
Faculty Development, also are designing
a series of monthly seminars for M. D.
Anderson clinicians on "Dealing with
Difficult Situations." The seminars,
which will begin in the fall of 2003, will
show clips from the video "On Being an
Oncologist: Reflections on the Personal
Dimensions of Clinical Oncology" (see
related article on page 6) to stimulate
discussion and may include role,playing
(Continued on page 6)
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The Cost of Caring
(Continued from page 5)
Dr. Ellen R.
Gritz , professor

and chair of the
Department of
Behavioral
Science, chairs
the Faculty
Health Commit,
tee at M. D.
Anderson.

exerci
on topic uch a how to deal
with an angry patient, Apted aid.
What l e can oncologi ts d to
minimize their tre ? Dr. Baile de cribed
ome wellne s practice that phy icians
have reported as being helpful. First,
he aid, clinicians have to do ome elf,
a e ment. "Ask your elf how much
you're overcommitted to work at the
price of other thing in your life, how
ati fying the job and work environment
are, and how much you're denying your
own needs," he said.
One of the most important wellne
practice is "adopting an approach to
life that' ba ed on a balance between
work, h me life, and relation hip and
friend , which can be great buffer
again t tre ,"Dr.Baile aid. Many
phy ician have made effort to implify
their live by hedding ome r pon i,
bilitie and focu ing more on taking
care of them elves. They may decide to
exerci e more, put more empha i on
pirituality, or tart regular meditation.
Attending a retreat that empha ize elf,
reflection, the ree tabli hment of goal
for the future, and renewal can al o be
extremely helpful. Many people, Dr.
Baile aid, go into medicine becau e
of the value they place on patient
care, healing, and helping other . It is
beneficial for these phy icians to have
an opportunity to "reexamine what are
the ati fying parts of practice in their
live and what aspect they're di ati ,
fied with and work on change where
that' po ible," he said. •

contact Dr. Baile
at (713) 792,7546 , Dr. Sazama at (713)
792,7791 , Dr. Gritz at (713) 745,3187 ,
or Janis Apted at (713) 792,8061 .
FOR MORE INFORMATION ,
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Excerpts from Focus Groups Featured in
Video to Help Oncologists Cope with Stress
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by Karen Stuyck
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Chemoprevention:
Preventing Cancer with a Pill
hen most people
think of cancer
prevention, they
envision such
activities as stopping smoking,
using sunscreen, _and eating
more fruits and vegetables.
In addition to these precautions,
however, another approach,
called chemoprevention, is
gaining ground. Chemoprevention,
which is being tested in many
different types of cancer, makes
use of natural or synthetic
substances to prevent cancer.
Researchers have identified about
400 drugs, vitamins, hormones, and
other agents that may help prevent
cancer, according to the N ational
Cancer Institute (NCI). C linical trials
(research studies involving people) are
under way to investigate more than
40 of these potential chemopreventive
agents. These clinical trials, which
usually involve healthy people who
have a higheMhan-average risk of
cancer, compare the incidence of
cancer in people who took the
chemopreventive agent with the
incidence in those who did not.
Scientists now see cancer as the
result of a multistage disease process
called carcinogenesis. Twenty years
or more may pass from the start of the
disease process, when the first cells
begin to mutate, until the latter stages
when the cancer is advanced. By using
chemopreventive compounds during the
early stages of carcinogenesis, researchers
hope to stop the cancer from developing.

Preventing breast cancer
in women at high risk
One of the first studies to show
the effectiveness of a chemopreventive
agent was the Breast Cancer Prevention
Trial, which concluded in 1998. In the
trial, healthy women at high risk of

acid, was shown to be effective in
breast cancer were randomly divided
preventing
second primary tumors in
into two groups. One group was given
patients
who
had been successfully
the chemoprevention drug tamoxifen,
treated
for
head
and neck cancer.
while the other group took a placebo.
Several
ongoing
clinical trials
The group that took tamoxifen had
concern
the
prevention
of colon cancer.
49% fewer cases of breast cancer than
In
some
studies,
people
with
a family
the placebo, or control, group.
history
of
colon
polyps
Tamoxifen interferes
or
cancer
are
taking
with the female horResearchers have
NSAIDs, such as
mone estrogen, which
identified about
aspirin or celecoxib,
breast cancer cells
400
drugs,
vitamins,
in hopes of preventing
need to grow and
colorectal
cancer.
divide.
hormones, and other
People
who
have been
Currently, the
agents that may help
Study of Tamoxifen
previously diagnosed
prevent cancer.
and Raloxifene (STAR)
with colon polyps or
trial is comparing
cancer are participattamoxifen with another drug,
ing in chemoprevention clinical trials
raloxifene, in hopes that raloxifene will
that study calcium compounds as
be equally effective in preventing breast preventive agents.
cancer but cause fewer adverse effects.
Both tamoxifen and raloxifene are
Lowering cancer risk
selective estrogen-receptor modulators,
in the general population
one class of promising chemopreventive
While researchers so far have
agents. Other compounds being studied
focused their chemopreventive studies
in clinical trials to determine their ability on people at higher risk of cancer, longto prevent cancer include nonsteroidal
term clinical trials with thousands of
anti-inflammatory drugs (NSAIDs),
participants will be needed to determine
calcium compounds, glucocorticoids (a
whether a substance will lower the risk
type of steroid), and retinoids (derivaof cancer in the general population.
tives of vitamin A).
More information about current
chemoprevention clinical trials is
Chemoprevention studies
available by calling the Cancer Informain other cancers
tion Service (1-800-4-CANCER) or
In addition to breast cancer,
by visiting the clinical trials page of
researchers are investigating the use
the NCl's Web site (http://cancer.gov/
of chemopreventive agents to prevent
clinical_trials/) or M. D. Anderson's
cancers of the colon, head and neck,
chemoprevention Web site (http://
prostate, esophagus, bladder, lung,
www.mdanderson.org/topics/
cervix, and skin.
chemoprev). •
In the largest cancer prevention
study ever conducted, researchers at
For more information, contact
M. D. Anderson Cancer Center and
your physician or contact the
approximately 400 other institutions
M.
D . Anderson Information Line:
are recruiting more than 32,000 men
to participate in the Selenium and
({) (800) 392-1611 within
Vitamin E Cancer Prevention Trial
the United States, or
(SELECT). This trial is investigating
({) (713) 792-6161 in Houston
whether supplements of vitamin E
and outside the United States.
and the dietary mineral selenium can
help prevent prostate cancer.
In another M. D. Anderson study, a
April 2003
derivative of vitamin A, 13-cis-retinoic
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Lung Cancer 2003;40(1 ):25-32.
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